NCT07084051 (I-MAS) is a NA clinical trial of I-MAS in Stroke (CVA) or Transient Ischemic Attack, sponsored by Hend Mansoor.

Who is sponsoring NCT07084051?

NCT07084051 is sponsored by Hend Mansoor.

What drugs are being tested in NCT07084051?

Interventions in NCT07084051: I-MAS.

What condition does NCT07084051 study?

NCT07084051 studies Stroke (CVA) or Transient Ischemic Attack.

Is NCT07084051 still recruiting?

NCT07084051 is currently completed. Last updated 26 January 2026.

Last reviewed 2026-01-26 · How we verify

NCT07084051: I-MAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improve Medication Adherence Among Stroke Survivors in Rural Kentucky

Completed NA Last updated 26 January 2026

What this trial tests

NA trial testing I-MAS in Stroke (CVA) or Transient Ischemic Attack in 4 participants. Completed in 31 December 2025.

Timeline

24 July 2025

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Hend Mansoor
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	24 July 2025
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across United States

Drugs / interventions tested

I-MAS

Conditions studied

Stroke (CVA) or Transient Ischemic Attack — all drugs for Stroke (CVA) or Transient Ischemic Attack →

Sponsor

Hend Mansoor

Who can join

Adults 30 to 90, any sex, with Stroke (CVA) or Transient Ischemic Attack. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To test the feasibility and promise of a combined intervention provided by community health worker (CHW) in collaboration with pharmacy technician and pharmacist to improve hypertension and long-term stroke outcomes by identifying and reducing barriers to medication adherence among ischemic stroke survivors. This collaborative intervention involves a self-management program including an educational session on practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc.), complemented by individually-tailored sessions to identify and address barriers to medication adherence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke (CVA) or Transient Ischemic Attack

Currently open trials in the same condition.

NCT07266662 — Comparative Effects of Sensory Augmentation and Neuromodulation on Enhancing Motor Recovery Among Stroke Survivors · NA · recruiting
NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
NCT07113041 — Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke · NA · recruiting
NCT05780905 — Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07084051 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hend Mansoor
Last refreshed: 26 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07084051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing